Skip to Content
Get facts about myelofibrosis treatment options here

Norditropin FlexPro (somatropin) Disease Interactions

There are 9 disease interactions with Norditropin FlexPro (somatropin):

Major

Somatropin (Includes Norditropin FlexPro) ↔ Active Malignancy

Severe Potential Hazard, Moderate plausibility

Applies to: Brain/Intracranial Tumor, Breast Cancer, Lung Cancer, Prostate Cancer, Bladder Cancer, Skin Cancer

Somatropin is contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin should be discontinued if there is any evidence of recurrence.

Major

Somatropin (Includes Norditropin FlexPro) ↔ Acute Critical Illness

Severe Potential Hazard, Moderate plausibility

Applies to: Acute (Surgical) Abdomen, Pulmonary Impairment, Sepsis

Treatment with somatropin is contraindicated in patients with acute critical illness due to any complications following open heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure. Patients with these conditions have an increased risk of mortality.

Major

Somatropin (Includes Norditropin FlexPro) ↔ Diabetic Retinopathy

Severe Potential Hazard, High plausibility

Applies to: Diabetic Retinopathy

Somatropin is contraindicated in patients with active proliferative or severe non- proliferative diabetic retinopathy.

Major

Somatropin (Includes Norditropin FlexPro) ↔ Prader-Willi Syndrome

Severe Potential Hazard, Moderate plausibility

Applies to: Prader-Willi Syndrome

Somatropin is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients.

Moderate

Growth Hormone (Includes Norditropin FlexPro) ↔ Diabetes

Moderate Potential Hazard, Moderate plausibility

Applies to: Diabetes Mellitus

The use of growth hormone has been associated with resistance to insulin. Patients with diabetes mellitus or impaired glucose tolerance should be observed closely during therapy. The dose of antihyperglycemic drugs (insulin or oral/injectable agents) may require adjustment.

References

  1. "Product Information. Protropin (somatrem)." Genentech, South San Francisco, CA.
  2. "Product Information. Nutropin (somatropin)." Genentech, South San Francisco, CA.
Moderate

Growth Hormone (Includes Norditropin FlexPro) ↔ Hypothyroidism

Moderate Potential Hazard, Moderate plausibility

Applies to: Hypothyroidism

The use of growth hormone has been associated with the development of hypothyroidism. Patients should be monitored baseline and periodically for adequate thyroid function. Inadequate treatment of hypothyroidism may inhibit the optimal response to growth hormone.

References

  1. "Product Information. Nutropin (somatropin)." Genentech, South San Francisco, CA.
  2. "Product Information. Protropin (somatrem)." Genentech, South San Francisco, CA.
Moderate

Somatropin (Includes Norditropin FlexPro) ↔ Intracranial Hypertension

Moderate Potential Hazard, Moderate plausibility

Applies to: Intracranial Hypertension, Papilledema Associated with Increased Intracranial Pressure

Intracranial hypertension with papilledema, visual changes, nausea and/or vomiting has been reported in a small number of patients treated with somatropin. Fundoscopic examination should be performed before treatment initiation to exclude preexisting papilledema, and should be continued periodically during treatment. If papilledema is observed during treatment, therapy should be stopped. Treatment could be restarted at a lower dose once intracranial hypertension has been resolved. Patients with Turner Syndrome might be at increased risk of developing intracranial hypertension.

Moderate

Somatropin (Includes Norditropin FlexPro) ↔ Scoliosis

Moderate Potential Hazard, Moderate plausibility

Applies to: Prader-Willi Syndrome, Turner's Syndrome, Scoliosis

Progression of scoliosis can occur in patients who experience rapid growth. Since somatropin increases growth rate, children with a history of scoliosis should be monitored for progression of this condition. Physicians should be alert for this skeletal abnormality which can be commonly seen in patients with Turner and Prader-Willi syndromes, and can manifest during somatropin treatment.

Moderate

Somatropin (Includes Norditropin FlexPro) ↔ Turner Syndrome

Moderate Potential Hazard, Moderate plausibility

Applies to: Turner's Syndrome

Somatropin may increase the risk of otitis media in patients with Turner syndrome. These patients should be evaluated carefully for otitis media and other ear disorders as they have an increased risk of ear and hearing disorders.

Norditropin FlexPro (somatropin) drug Interactions

There are 227 drug interactions with Norditropin FlexPro (somatropin)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2016 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide